Asahi Life Asset Management CO. LTD. Invests $440,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Asahi Life Asset Management CO. LTD. acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report) in the third quarter, Holdings Channel.com reports. The fund acquired 1,600 shares of the biopharmaceutical company’s stock, valued at approximately $440,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC bought a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $26,000. Allspring Global Investments Holdings LLC raised its position in Alnylam Pharmaceuticals by 572.0% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 143 shares during the period. Friedenthal Financial bought a new stake in Alnylam Pharmaceuticals in the third quarter worth $51,000. Altitude Crest Partners Inc. purchased a new stake in Alnylam Pharmaceuticals during the first quarter valued at about $30,000. Finally, Meeder Asset Management Inc. grew its stake in shares of Alnylam Pharmaceuticals by 1,237.5% during the second quarter. Meeder Asset Management Inc. now owns 321 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 297 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ALNY. Citigroup raised their price target on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price target for the stock from $198.00 to $370.00 in a report on Friday, August 16th. Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Wells Fargo & Company raised their target price on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a research note on Friday, August 2nd. Finally, Bank of America lifted their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Six investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $290.86.

Get Our Latest Stock Analysis on ALNY

Insider Activity at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,148 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total value of $4,089,960.00. Following the transaction, the chief executive officer now directly owns 73,441 shares in the company, valued at $19,829,070. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, CEO Yvonne Greenstreet sold 15,148 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $270.00, for a total transaction of $4,089,960.00. Following the transaction, the chief executive officer now owns 73,441 shares in the company, valued at $19,829,070. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Dennis A. Ausiello sold 20,250 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the transaction, the director now owns 136 shares in the company, valued at $35,632. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 50,398 shares of company stock worth $13,595,460 over the last quarter. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock traded up $3.91 during mid-day trading on Monday, hitting $288.77. The company’s stock had a trading volume of 71,490 shares, compared to its average volume of 866,008. The stock has a market cap of $36.53 billion, a price-to-earnings ratio of -106.29 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39. The business has a 50-day moving average price of $274.43 and a 200 day moving average price of $222.40.

Alnylam Pharmaceuticals (NASDAQ:ALNYGet Free Report) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million during the quarter, compared to analysts’ expectations of $447.22 million. Alnylam Pharmaceuticals’s quarterly revenue was up 107.0% compared to the same quarter last year. During the same period last year, the firm posted ($2.21) EPS. Equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

(Free Report)

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Read More

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNYFree Report).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.